FLT3 inhibitors in acute myeloid leukemia: increasing options
Clin Adv Hematol Oncol. 2021 Jun;19(6):352-355.NO ABSTRACTPMID:34106908 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Tapan M Kadia Source Type: research

How I manage chronic lymphocytic leukemia
Clin Adv Hematol Oncol. 2021 Jun;19(6):360-364.NO ABSTRACTPMID:34106909 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Nitin Jain Source Type: research

Sentinel lymph node biopsy and completion lymph node dissection in melanoma
Clin Adv Hematol Oncol. 2021 Jun;19(6):368-371.NO ABSTRACTPMID:34106910 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Merrick I Ross Source Type: research

Are novel agents ready to assume the mantle in the frontline treatment of mantle cell lymphoma?
Clin Adv Hematol Oncol. 2021 Jun;19(6):376-382.ABSTRACTAlthough chemotherapy has been a mainstay of the frontline treatment of mantle cell lymphoma (MCL) for many years, novel agents-including Bruton kinase inhibitors, immunomodulatory agents, and BCL2 inhibitors-have shown promise in patients with relapsed and refractory disease, and they are also being studied in the frontline setting. This review summarizes the current clinical data for using these novel agents in untreated MCL, both in combination with chemotherapy and singly, and discusses some of the trials currently under way to assess their future potential.PMID:34...
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Samuel Yamshon Peter Martin Source Type: research

The optimal duration of endocrine therapy in hormone receptor-positive breast cancer
Clin Adv Hematol Oncol. 2021 Jun;19(6):383-404.NO ABSTRACTPMID:34106912 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: George W Sledge Source Type: research

Incorporating palliative care into oncology practice: why and how
Clin Adv Hematol Oncol. 2021 Jun;19(6):390-395.ABSTRACTThe provision of specialty palliative care alongside oncology care is now recommended by the American Society of Clinical Oncology (ASCO) on the basis of multiple randomized trials showing that it leads to better symptom control, less depression and anxiety, improved quality of life, improved caregiver quality of life, and even longer survival. That said, simply not enough palliative care specialists are available to provide concurrent care, so oncologists are tasked with providing the greatest part of primary palliative care. It is useful to think of primary palliativ...
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Qasim Hussaini Thomas J Smith Source Type: research

FLT3 inhibitors in acute myeloid leukemia: increasing options
Clin Adv Hematol Oncol. 2021 Jun;19(6):352-355.NO ABSTRACTPMID:34106908 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Tapan M Kadia Source Type: research

How I manage chronic lymphocytic leukemia
Clin Adv Hematol Oncol. 2021 Jun;19(6):360-364.NO ABSTRACTPMID:34106909 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Nitin Jain Source Type: research

Sentinel lymph node biopsy and completion lymph node dissection in melanoma
Clin Adv Hematol Oncol. 2021 Jun;19(6):368-371.NO ABSTRACTPMID:34106910 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Merrick I Ross Source Type: research

Are novel agents ready to assume the mantle in the frontline treatment of mantle cell lymphoma?
Clin Adv Hematol Oncol. 2021 Jun;19(6):376-382.ABSTRACTAlthough chemotherapy has been a mainstay of the frontline treatment of mantle cell lymphoma (MCL) for many years, novel agents-including Bruton kinase inhibitors, immunomodulatory agents, and BCL2 inhibitors-have shown promise in patients with relapsed and refractory disease, and they are also being studied in the frontline setting. This review summarizes the current clinical data for using these novel agents in untreated MCL, both in combination with chemotherapy and singly, and discusses some of the trials currently under way to assess their future potential.PMID:34...
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Samuel Yamshon Peter Martin Source Type: research

The optimal duration of endocrine therapy in hormone receptor-positive breast cancer
Clin Adv Hematol Oncol. 2021 Jun;19(6):383-404.NO ABSTRACTPMID:34106912 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: George W Sledge Source Type: research

Incorporating palliative care into oncology practice: why and how
Clin Adv Hematol Oncol. 2021 Jun;19(6):390-395.ABSTRACTThe provision of specialty palliative care alongside oncology care is now recommended by the American Society of Clinical Oncology (ASCO) on the basis of multiple randomized trials showing that it leads to better symptom control, less depression and anxiety, improved quality of life, improved caregiver quality of life, and even longer survival. That said, simply not enough palliative care specialists are available to provide concurrent care, so oncologists are tasked with providing the greatest part of primary palliative care. It is useful to think of primary palliativ...
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Qasim Hussaini Thomas J Smith Source Type: research

FLT3 inhibitors in acute myeloid leukemia: increasing options
Clin Adv Hematol Oncol. 2021 Jun;19(6):352-355.NO ABSTRACTPMID:34106908 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Tapan M Kadia Source Type: research

How I manage chronic lymphocytic leukemia
Clin Adv Hematol Oncol. 2021 Jun;19(6):360-364.NO ABSTRACTPMID:34106909 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Nitin Jain Source Type: research

Sentinel lymph node biopsy and completion lymph node dissection in melanoma
Clin Adv Hematol Oncol. 2021 Jun;19(6):368-371.NO ABSTRACTPMID:34106910 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Merrick I Ross Source Type: research

Are novel agents ready to assume the mantle in the frontline treatment of mantle cell lymphoma?
Clin Adv Hematol Oncol. 2021 Jun;19(6):376-382.ABSTRACTAlthough chemotherapy has been a mainstay of the frontline treatment of mantle cell lymphoma (MCL) for many years, novel agents-including Bruton kinase inhibitors, immunomodulatory agents, and BCL2 inhibitors-have shown promise in patients with relapsed and refractory disease, and they are also being studied in the frontline setting. This review summarizes the current clinical data for using these novel agents in untreated MCL, both in combination with chemotherapy and singly, and discusses some of the trials currently under way to assess their future potential.PMID:34...
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Samuel Yamshon Peter Martin Source Type: research

The optimal duration of endocrine therapy in hormone receptor-positive breast cancer
Clin Adv Hematol Oncol. 2021 Jun;19(6):383-404.NO ABSTRACTPMID:34106912 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: George W Sledge Source Type: research

Incorporating palliative care into oncology practice: why and how
Clin Adv Hematol Oncol. 2021 Jun;19(6):390-395.ABSTRACTThe provision of specialty palliative care alongside oncology care is now recommended by the American Society of Clinical Oncology (ASCO) on the basis of multiple randomized trials showing that it leads to better symptom control, less depression and anxiety, improved quality of life, improved caregiver quality of life, and even longer survival. That said, simply not enough palliative care specialists are available to provide concurrent care, so oncologists are tasked with providing the greatest part of primary palliative care. It is useful to think of primary palliativ...
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Qasim Hussaini Thomas J Smith Source Type: research

FLT3 inhibitors in acute myeloid leukemia: increasing options
Clin Adv Hematol Oncol. 2021 Jun;19(6):352-355.NO ABSTRACTPMID:34106908 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Tapan M Kadia Source Type: research

How I manage chronic lymphocytic leukemia
Clin Adv Hematol Oncol. 2021 Jun;19(6):360-364.NO ABSTRACTPMID:34106909 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Nitin Jain Source Type: research

Sentinel lymph node biopsy and completion lymph node dissection in melanoma
Clin Adv Hematol Oncol. 2021 Jun;19(6):368-371.NO ABSTRACTPMID:34106910 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Merrick I Ross Source Type: research

Are novel agents ready to assume the mantle in the frontline treatment of mantle cell lymphoma?
Clin Adv Hematol Oncol. 2021 Jun;19(6):376-382.ABSTRACTAlthough chemotherapy has been a mainstay of the frontline treatment of mantle cell lymphoma (MCL) for many years, novel agents-including Bruton kinase inhibitors, immunomodulatory agents, and BCL2 inhibitors-have shown promise in patients with relapsed and refractory disease, and they are also being studied in the frontline setting. This review summarizes the current clinical data for using these novel agents in untreated MCL, both in combination with chemotherapy and singly, and discusses some of the trials currently under way to assess their future potential.PMID:34...
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Samuel Yamshon Peter Martin Source Type: research

The optimal duration of endocrine therapy in hormone receptor-positive breast cancer
Clin Adv Hematol Oncol. 2021 Jun;19(6):383-404.NO ABSTRACTPMID:34106912 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: George W Sledge Source Type: research

Incorporating palliative care into oncology practice: why and how
Clin Adv Hematol Oncol. 2021 Jun;19(6):390-395.ABSTRACTThe provision of specialty palliative care alongside oncology care is now recommended by the American Society of Clinical Oncology (ASCO) on the basis of multiple randomized trials showing that it leads to better symptom control, less depression and anxiety, improved quality of life, improved caregiver quality of life, and even longer survival. That said, simply not enough palliative care specialists are available to provide concurrent care, so oncologists are tasked with providing the greatest part of primary palliative care. It is useful to think of primary palliativ...
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Qasim Hussaini Thomas J Smith Source Type: research

FLT3 inhibitors in acute myeloid leukemia: increasing options
Clin Adv Hematol Oncol. 2021 Jun;19(6):352-355.NO ABSTRACTPMID:34106908 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Tapan M Kadia Source Type: research

How I manage chronic lymphocytic leukemia
Clin Adv Hematol Oncol. 2021 Jun;19(6):360-364.NO ABSTRACTPMID:34106909 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Nitin Jain Source Type: research

Sentinel lymph node biopsy and completion lymph node dissection in melanoma
Clin Adv Hematol Oncol. 2021 Jun;19(6):368-371.NO ABSTRACTPMID:34106910 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Merrick I Ross Source Type: research

Are novel agents ready to assume the mantle in the frontline treatment of mantle cell lymphoma?
Clin Adv Hematol Oncol. 2021 Jun;19(6):376-382.ABSTRACTAlthough chemotherapy has been a mainstay of the frontline treatment of mantle cell lymphoma (MCL) for many years, novel agents-including Bruton kinase inhibitors, immunomodulatory agents, and BCL2 inhibitors-have shown promise in patients with relapsed and refractory disease, and they are also being studied in the frontline setting. This review summarizes the current clinical data for using these novel agents in untreated MCL, both in combination with chemotherapy and singly, and discusses some of the trials currently under way to assess their future potential.PMID:34...
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Samuel Yamshon Peter Martin Source Type: research

The optimal duration of endocrine therapy in hormone receptor-positive breast cancer
Clin Adv Hematol Oncol. 2021 Jun;19(6):383-404.NO ABSTRACTPMID:34106912 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: George W Sledge Source Type: research

Incorporating palliative care into oncology practice: why and how
Clin Adv Hematol Oncol. 2021 Jun;19(6):390-395.ABSTRACTThe provision of specialty palliative care alongside oncology care is now recommended by the American Society of Clinical Oncology (ASCO) on the basis of multiple randomized trials showing that it leads to better symptom control, less depression and anxiety, improved quality of life, improved caregiver quality of life, and even longer survival. That said, simply not enough palliative care specialists are available to provide concurrent care, so oncologists are tasked with providing the greatest part of primary palliative care. It is useful to think of primary palliativ...
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Qasim Hussaini Thomas J Smith Source Type: research

FLT3 inhibitors in acute myeloid leukemia: increasing options
Clin Adv Hematol Oncol. 2021 Jun;19(6):352-355.NO ABSTRACTPMID:34106908 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Tapan M Kadia Source Type: research

How I manage chronic lymphocytic leukemia
Clin Adv Hematol Oncol. 2021 Jun;19(6):360-364.NO ABSTRACTPMID:34106909 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Nitin Jain Source Type: research

Sentinel lymph node biopsy and completion lymph node dissection in melanoma
Clin Adv Hematol Oncol. 2021 Jun;19(6):368-371.NO ABSTRACTPMID:34106910 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Merrick I Ross Source Type: research

Are novel agents ready to assume the mantle in the frontline treatment of mantle cell lymphoma?
Clin Adv Hematol Oncol. 2021 Jun;19(6):376-382.ABSTRACTAlthough chemotherapy has been a mainstay of the frontline treatment of mantle cell lymphoma (MCL) for many years, novel agents-including Bruton kinase inhibitors, immunomodulatory agents, and BCL2 inhibitors-have shown promise in patients with relapsed and refractory disease, and they are also being studied in the frontline setting. This review summarizes the current clinical data for using these novel agents in untreated MCL, both in combination with chemotherapy and singly, and discusses some of the trials currently under way to assess their future potential.PMID:34...
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Samuel Yamshon Peter Martin Source Type: research

The optimal duration of endocrine therapy in hormone receptor-positive breast cancer
Clin Adv Hematol Oncol. 2021 Jun;19(6):383-404.NO ABSTRACTPMID:34106912 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: George W Sledge Source Type: research

Incorporating palliative care into oncology practice: why and how
Clin Adv Hematol Oncol. 2021 Jun;19(6):390-395.ABSTRACTThe provision of specialty palliative care alongside oncology care is now recommended by the American Society of Clinical Oncology (ASCO) on the basis of multiple randomized trials showing that it leads to better symptom control, less depression and anxiety, improved quality of life, improved caregiver quality of life, and even longer survival. That said, simply not enough palliative care specialists are available to provide concurrent care, so oncologists are tasked with providing the greatest part of primary palliative care. It is useful to think of primary palliativ...
Source: Clinical Advances in Hematology and Oncology - June 9, 2021 Category: Cancer & Oncology Authors: Qasim Hussaini Thomas J Smith Source Type: research

Asciminib for the treatment of patients with chronic myeloid leukemia
Clin Adv Hematol Oncol. 2021 Apr;19(4):207-208.NO ABSTRACTPMID:33989269 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 14, 2021 Category: Cancer & Oncology Authors: Jorge Cortes Source Type: research

Should venetoclax be used with or without anti-CD20 therapy for CLL?
Clin Adv Hematol Oncol. 2021 Apr;19(4):209-211.NO ABSTRACTPMID:33989270 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 14, 2021 Category: Cancer & Oncology Authors: Richard R Furman Source Type: research

Determining the optimal duration of adjuvant therapy in colon cancer
Clin Adv Hematol Oncol. 2021 Apr;19(4):220-222.NO ABSTRACTPMID:33989271 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 14, 2021 Category: Cancer & Oncology Authors: Jeffrey A Meyerhardt Source Type: research

New approaches to targeting the androgen receptor pathway in prostate cancer
Clin Adv Hematol Oncol. 2021 Apr;19(4):228-240.ABSTRACTThe androgen signaling axis has been the main therapeutic target in the management of advanced prostate cancer for several decades. Over the past years, significant advances have been made in terms of a better understanding the androgen receptor (AR) pathway and mechanisms of castration resistance, along with the development of more potent AR-targeted therapies. New drugs, such as abiraterone, enzalutamide, apalutamide, and darolutamide, have been approved for castration-resistant prostate cancer and also have demonstrated an overall survival benefit in the castration-...
Source: Clinical Advances in Hematology and Oncology - May 14, 2021 Category: Cancer & Oncology Authors: Pedro Isaacsson Velho Diogo Assed Bastos Emmanuel S Antonarakis Source Type: research

Local and regional therapy for primary and locally recurrent melanoma
Clin Adv Hematol Oncol. 2021 Apr;19(4):246-260.ABSTRACTIn the vast majority of cases, cutaneous melanoma presents as localized disease and is treated with wide excision and sentinel lymph node biopsy, with shared decision making regarding completion lymph node dissection and adjuvant systemic therapy. The treatment of recurrent and in-transit disease is more complex, with further options for regional and systemic therapies and multiple variables to be factored into decisions. Rates of overall and complete response to regional therapies can be quite high in carefully chosen patients, which limits the need for systemic thera...
Source: Clinical Advances in Hematology and Oncology - May 14, 2021 Category: Cancer & Oncology Authors: Justin G Wilkes Ayushi Patel Jonathan S Zager Source Type: research

Recently approved drugs herald a new era in therapy for diffuse large B-cell lymphoma
Clin Adv Hematol Oncol. 2021 May;19(5):284-287.NO ABSTRACTPMID:33989274 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 14, 2021 Category: Cancer & Oncology Authors: Grzegorz S Nowakowski Source Type: research

The use of telemedicine in hematology and oncology
Clin Adv Hematol Oncol. 2021 May;19(5):292-294.NO ABSTRACTPMID:33989275 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 14, 2021 Category: Cancer & Oncology Authors: William Wood Source Type: research

Chimeric antigen receptor T-cell therapy plus checkpoint blockade in thoracic cancers
Clin Adv Hematol Oncol. 2021 May;19(5):295-297.NO ABSTRACTPMID:33989276 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 14, 2021 Category: Cancer & Oncology Authors: Prasad S Adusumilli Source Type: research

What's next for immunotherapy in locally advanced NSCLC?
Clin Adv Hematol Oncol. 2021 May;19(5):302-304.NO ABSTRACTPMID:33989277 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 14, 2021 Category: Cancer & Oncology Authors: Neal Edward Ready Source Type: research

The evolving role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer
Clin Adv Hematol Oncol. 2021 May;19(5):305-315.ABSTRACTTriple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer for which chemotherapy had been the only active treatment option once metastatic disease developed. Immune checkpoint inhibitors (ICIs) are now available to treat patients with advanced TNBC who have programmed cell death ligand 1 (PD-L1)-positive tumors; these agents have been shown to improve clinical outcomes. Additionally, long-term disease control can be achieved in a subset of patients. Continued investigations of ICIs and optimal combinations with chemotherapy and targeted agents to e...
Source: Clinical Advances in Hematology and Oncology - May 14, 2021 Category: Cancer & Oncology Authors: Meghan Steiner Antoinette R Tan Source Type: research

Lenalidomide in DLBCL: are we past the cell of origin?
Clin Adv Hematol Oncol. 2021 May;19(5):320-325.ABSTRACTSingle-agent lenalidomide has modest activity in diffuse large B-cell lymphoma (DLBCL) and is thought to be more potent in activated B-cell (ABC) lymphomas, which are more treatment-resistant. However, the addition of lenalidomide to rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in randomized clinical trials has shown equivocal benefit, despite phase 2 studies that suggested otherwise. These equivocal results suggest that either the cell of origin (COO) has limited importance for prescribing lenalidomide, or that lenalidomide is not...
Source: Clinical Advances in Hematology and Oncology - May 14, 2021 Category: Cancer & Oncology Authors: Mendel Goldfinger Dennis L Cooper Source Type: research

Asciminib for the treatment of patients with chronic myeloid leukemia
Clin Adv Hematol Oncol. 2021 Apr;19(4):207-208.NO ABSTRACTPMID:33989269 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 14, 2021 Category: Cancer & Oncology Authors: Jorge Cortes Source Type: research

Should venetoclax be used with or without anti-CD20 therapy for CLL?
Clin Adv Hematol Oncol. 2021 Apr;19(4):209-211.NO ABSTRACTPMID:33989270 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 14, 2021 Category: Cancer & Oncology Authors: Richard R Furman Source Type: research

Determining the optimal duration of adjuvant therapy in colon cancer
Clin Adv Hematol Oncol. 2021 Apr;19(4):220-222.NO ABSTRACTPMID:33989271 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 14, 2021 Category: Cancer & Oncology Authors: Jeffrey A Meyerhardt Source Type: research